Headache is a common side effect of some cancer medicines. On acalabrutinib it mostly comes in the first weeks, is mild and eases. On blinatumomab it can be a sign of a reaction that your team needs to know about. A sudden severe headache, or one with weakness, confusion, a fit or trouble speaking, is an emergency. Your own team's advice comes first.
No oncology guideline on drug-related headache was found; this page joins a general headache guideline to what the labels and three narrative papers say, and the local protocol comes first. Assessment: NICE CG150 (England, over 12s) lists the features that call for evaluation and consideration of investigation or referral (1.1.1 [2012]), and separately a new-onset headache with compromised immunity, a history of malignancy known to metastasise to the brain, or vomiting without other obvious cause (1.1.2 [2012]). The UKONS triage tool (v3) asks about headache in its pain row and says to consider ICANS or CRS.
Acalabrutinib: headache is in 22% to 40% of patients across the trials in the US label (0.6% to 1.7% at grade 3 or above; two of the five tables print grade 3 or 4) and 36.5% on monotherapy in the EU SmPC (grade 3 or higher 1.2%). Three narrative papers, none graded, describe it as early and mild or grade 1 or 2. Two suggest paracetamol or caffeine, avoiding NSAIDs if possible (O'Brien 2021, written with AstraZeneca-funded support, and the Chinese consensus 2023, which follows it); Lipsky and Lamanna 2020 say paracetamol with or without caffeine is often effective and do not mention NSAIDs. Grade 3 or greater non-haematological toxicity is an interruption in both labels (monotherapy or with obinutuzumab): resume at the same dose the first and second time, 100 mg once daily the third, discontinue at the fourth. Both labels warn of serious and fatal bleeding (the EU SmPC names central nervous system haemorrhage; the US label counts any central nervous system bleeding as major haemorrhage); the US patient information lists a headache that lasts a long time among the signs of bleeding to report right away, and the EU leaflet's list does not name headache.
Blinatumomab: the US label gives headache and tremor as the most common manifestations of neurological toxicity, marks headache in its tables as possibly representing ICANS, and lists it among the manifestations of CRS; the EU SmPC recommends a neurological examination before starting. Grading and treatment of ICANS and CRS are in their own protocols. Trastuzumab emtansine (headache 28% in both US label trials) and talazoparib (33% in EMBRACA in the US label, 19.0% in the EU pooled data) list headache with no rule for managing it; talazoparib's labels withhold for grade 3 or 4 non-haematological reactions. For trastuzumab emtansine the only wording that names headache is in the EU texts: the package leaflet says not to drive, cycle or use tools or machines until a headache stops. Both trastuzumab emtansine labels warn of central nervous system haemorrhage and do not connect it to headache.
Why: The UKONS triage tool puts this question in its pain row, beside asking whether the pain is new, how long it has lasted and whether painkillers have been taken. It gives no reason and does not say for which treatments. The blinatumomab label reports both ICANS and cytokine release syndrome with that medicine.
“Do you have a headache? consider ICANS/CRS”
Why: This is NICE's list for anyone over 12 presenting with headache; the list also includes symptoms of giant cell arteritis, signs of acute narrow angle glaucoma and a substantial change in the character of the headache. NICE points to its suspected cancer guideline for suspected brain tumours. For people on acalabrutinib, the EU SmPC separately asks doctors to consider PML, a brain infection, when there are new or worsening neurological, cognitive or behavioural signs.
“Evaluate people who present with headache and any of the following features, and consider the need for further investigations and/or referral:”
NICE 2025 · [2012]
Why: NICE lists these three, with age under 20 and a history of malignancy as a fourth, and gives immunosuppressive drugs as an example of a cause of compromised immunity. It states no reason in the recommendation. Headache from raised pressure in the head has its own protocol on this site.
“a history of malignancy known to metastasise to the brain”
NICE 2025 · [2012]
Why: The EU SmPC recommends both and gives a writing test as an example of monitoring. It says that among patients who had a neurological event the median time to the first was within the first 2 weeks of treatment.
“It is recommended that a neurological examination be performed in patients prior to starting BLINCYTO therapy and that patients be clinically monitored for signs and symptoms of neurologic events including ICANS”
Why: The US label says the most common manifestations of neurological toxicity were headache and tremor, marks headache in its side-effect tables with the note that it may represent ICANS, and lists headache among the manifestations of cytokine release syndrome. It says management may require interrupting or discontinuing blinatumomab or corticosteroids, as set out in the ICANS and cytokine release protocols.
“Monitor patients receiving BLINCYTO for signs and symptoms of neurological toxicities, including ICANS.”
Why: Both labels report serious and fatal bleeding on acalabrutinib. The EU SmPC names central nervous system haemorrhage among the major events, and the US label counts any central nervous system bleeding as major haemorrhage. The US patient information lists a headache that lasts a long time, with dizziness, weakness, confusion and changes in speech, among the signs of bleeding to tell the healthcare provider about right away. The EU leaflet's list of bleeding symptoms does not name headache. The US label says antithrombotic medicines may further increase the risk.
“Monitor patients for signs of bleeding.”
Why: This is the only instruction about headache in the trastuzumab emtansine texts read, and it is in the EU package leaflet, which lists headache beside blurred vision, tiredness and dizziness. The EU SmPC says the significance of headache for driving is unknown. The US label reports headache in 28% of patients in each of its two trials and gives no instruction about it. Both labels warn of bleeding, including in the central nervous system, and neither connects that warning to headache.
“If you experience flushing, shivering fits, fever, trouble breathing, low blood pressure or a rapid heartbeat (infusion-related reaction), blurred vision, tiredness, headache, or dizziness, do not drive, cycle, use tools or machines until these reactions stop.”
Why: A review written with manufacturer-funded support says that telling people beforehand reassures them, that these headaches usually come early in treatment, are mild and of limited duration, and should abate over a period of up to 4 weeks. It is a narrative review, not a graded guideline.
“Prior to treatment initiation: advise patients that headaches should abate quickly, are easily managed, and are not a long-term consequence of treatment”
Why: Two narrative papers say this in nearly the same words (O'Brien 2021, written with manufacturer-funded support, and the Chinese consensus 2023), and say that many of these headaches need no medical intervention. A third, Lipsky and Lamanna 2020, says paracetamol with or without caffeine is often effective and does not mention NSAIDs. Neither of the two gives a reason for avoiding NSAIDs in this passage, none of the three is graded, and no trial of any treatment for this headache was found.
“These headaches can be managed mostly without any medical interventions, or can be effectively treated using acetaminophen or caffeine, while avoiding the use of nonsteroidal anti-inflammatory drugs, if possible.”
Experimental Hematology & Oncology (Song et al.; states no funding and no competing interests) 2023
Why: This is what Macmillan tells people taking acalabrutinib, adding that the doctor, nurse or pharmacist can advise on painkillers that may help. Cancer Research UK asks people to let their doctor or nurse know about headaches and names paracetamol.
“Tell them if the headache does not get better, or gets worse.”
Why: NICE's recommendation, for anyone over 12 with headache in England; NICE gives no reason in the recommendation. It was not written for people on anticancer medicines, and no source read applies it to a headache caused by one. It is here only because the painkillers the other steps name are on NICE's list.
“Be alert to the possibility of medication overuse headache in people whose headache developed or worsened while they were taking the following drugs for 3 months or more:”
NICE 2025 · [2012]
Why: This is the labels' rule for any grade 3 or greater non-haematological toxicity, not a rule written for headache; neither label says how to manage a headache. The US label and the EU SmPC give the same steps; the SmPC names CTCAE version 5.0 for the grading. The US label has separate tables for acalabrutinib with bendamustine and rituximab and with venetoclax; the EU SmPC applies this table to the venetoclax combination as well and has a separate one for bendamustine and rituximab.
“Once toxicity has resolved to Grade 1 or baseline level, CALQUENCE may be resumed at 100 mg approximately every 12 hours.”
Why: This is the labels' rule for any grade 3 or 4 non-haematological adverse reaction, not one written for headache; neither label says how to manage a headache. The US label says a reduced dose and the EU SmPC the next lower dose. The US label reports headache in 33% of patients in the EMBRACA trial, 2% at grade 3, and the EU SmPC in 19.0% of 1 088 patients across 8 studies.
“Consider resuming TALZENNA at a reduced dose or discontinue”
Why: Macmillan lists these as the sudden symptoms of a stroke from bleeding on the brain, which it says this treatment can make more likely, and tells people not to drive themselves to hospital. The NHS page for the general public says to call 999 or go to A&E for a headache that started suddenly and is extremely painful, or one with a fit, numbness or weakness, drowsiness or confusion, or loss of vision.
“contact the hospital straight away on the 24-hour number”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
There is no graded oncology guideline for headache caused by an anticancer medicine, so no version can be called best supported. The strongest material read is general: NICE CG150's two lists of features that call for evaluation and for considering investigation or referral ([2012], ungraded, England), which include compromised immunity and a history of a cancer known to spread to the brain. For acalabrutinib, three narrative papers agree that the headache comes early and is mild or grade 1 or 2, and that paracetamol, with or without caffeine, helps. Two of them add avoiding NSAIDs if possible: one was written with AstraZeneca-funded medical writing support, and the Chinese consensus repeats it in a section that carries no recommendation category. No trial of any treatment for this headache was found. For blinatumomab, the US label and the UKONS triage tool both treat headache as a possible sign of ICANS or cytokine release syndrome. Dose rules are the labels' general rules for grade 3 or worse non-haematological toxicity, the same in the US and EU for acalabrutinib and for talazoparib.
NICE 2025 · UK Oncology Nursing Society (UKONS) 2024 · Frontiers in Oncology (O'Brien, Brown, Byrd, Furman et al.; medical writing funded by AstraZeneca, several authors declare AstraZeneca or Acerta ties) 2021 · Experimental Hematology & Oncology (Song et al.; states no funding and no competing interests) 2023 · Hematology, American Society of Hematology Education Program (Lipsky and Lamanna; one author declares advisory roles and research support from manufacturers including AstraZeneca) 2020 · Amgen / US FDA (DailyMed) 2026 · AstraZeneca Pharmaceuticals / US FDA (DailyMed) 2026 · AstraZeneca / European Medicines Agency 2026 · Pfizer / US FDA (DailyMed) 2026 · Pfizer / European Medicines Agency 2025
Where it differs: O'Brien 2021 and the Chinese consensus 2023 say paracetamol or caffeine, avoiding NSAIDs if possible. Lipsky and Lamanna 2020 say paracetamol with or without caffeine is often effective, and that the headache is often responsive to caffeine. Macmillan says the team can advise on painkillers and Cancer Research UK names paracetamol; neither mentions caffeine or NSAIDs. The NHS page for the general public suggests paracetamol or ibuprofen for an ordinary headache; it was not written for people on a medicine that raises the risk of bleeding.
Evidence: Narrative statements only. None of the three papers reports a trial or a dose of caffeine. The two that say to avoid NSAIDs give no reason in their headache passages, and Lipsky and Lamanna do not mention NSAIDs. O'Brien 2021 was written with medical writing support funded by AstraZeneca.
Frontiers in Oncology (O'Brien, Brown, Byrd, Furman et al.; medical writing funded by AstraZeneca, several authors declare AstraZeneca or Acerta ties) 2021 · Experimental Hematology & Oncology (Song et al.; states no funding and no competing interests) 2023 · Hematology, American Society of Hematology Education Program (Lipsky and Lamanna; one author declares advisory roles and research support from manufacturers including AstraZeneca) 2020 · Macmillan Cancer Support 2025 · Cancer Research UK 2024 · NHS 2024
Where it differs: The US label gives 22% (ASCEND) to 40% (ELEVATE-TN) across its trial tables, with 0.6% to 1.7% at grade 3 or above (the ECHO and AMPLIFY tables print grade 3 or 4). The EU SmPC gives 36.5% of 1 478 patients on monotherapy, 1.2% at grade 3 or higher. O'Brien 2021 gives 22% to 51%, says these headaches typically occur within 30 minutes of dosing, and that only 1% lead to treatment discontinuation. Lipsky and Lamanna 2020 say nearly 70% of patients in pivotal studies had grade 1 or 2 headaches, most often in weeks 1 to 3.
Evidence: The label figures are from registration trials with different populations and follow-up; the review figures are the authors' summaries of trials and were not checked against the trial reports here.
AstraZeneca Pharmaceuticals / US FDA (DailyMed) 2026 · AstraZeneca / European Medicines Agency 2026 · Frontiers in Oncology (O'Brien, Brown, Byrd, Furman et al.; medical writing funded by AstraZeneca, several authors declare AstraZeneca or Acerta ties) 2021 · Hematology, American Society of Hematology Education Program (Lipsky and Lamanna; one author declares advisory roles and research support from manufacturers including AstraZeneca) 2020
Where it differs: The US patient information lists "headache that lasts a long time" among the signs of bleeding to tell the healthcare provider about right away. The EU package leaflet tells people to stop taking Calquence and contact a doctor or go to the nearest emergency department immediately for bleeding symptoms, and its list (black or bloody stools, pink or brown urine, nosebleeds, bruising, unexpected bleeding, vomiting or coughing up blood, dizziness, weakness, confusion) does not name headache; it lists headache as a very common other side effect. Macmillan names a severe headache as a stroke symptom (hospital straight away or 999); Cancer Research UK lists headache among the symptoms of bleeding in the brain.
Evidence: Regulatory patient texts and charity pages; none gives a figure for how often a headache on acalabrutinib is a bleed. The EU SmPC reports intracranial haemorrhage in 0.1% on monotherapy; the US label reports major haemorrhage, which counts any central nervous system bleeding, in 4.7% of 2,055 patients.
AstraZeneca Pharmaceuticals / US FDA (DailyMed) 2026 · AstraZeneca / European Medicines Agency 2026 · Macmillan Cancer Support 2025 · Cancer Research UK 2024
Where it differs: The US Medication Guide lists headache among the symptoms of both cytokine release syndrome and neurologic problems, under an instruction to call the healthcare provider or get emergency medical help right away. The EU leaflet lists headache, with sleeplessness and shaking, as a very common side effect that may be a symptom of ICANS; its list of things to tell the doctor about immediately names shaking, confusion, encephalopathy, difficulty communicating and seizure, and not headache. The EU SmPC recommends a neurological examination before treatment; the US label asks for monitoring and for outpatients to be advised to make contact. Cancer Research UK lists headaches among the symptoms of ICANS, under the words to tell the doctor or call 999 straight away.
Evidence: Regulatory labels. The US label reports neurological toxicities in approximately 65% of patients in trials and signs and symptoms consistent with ICANS in 7.5%; the EU SmPC reports headache in 32.7%.
Amgen / US FDA (DailyMed) 2026 · Amgen / European Medicines Agency 2026 · Cancer Research UK 2026
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Evaluate, and consider investigation or referral for, headache with any of the listed features (NICE 1.1.1) “Evaluate people who present with headache and any of the following features, and consider the need for further investigations and/or referral:” | [2012] | NICE 2025 |
| Consider investigation or referral for new-onset headache with compromised immunity, caused for example by immunosuppressive drugs (NICE 1.1.2) “compromised immunity, caused, for example, by HIV or immunosuppressive drugs” | [2012] | NICE 2025 |
| Consider investigation or referral for new-onset headache with a history of malignancy known to metastasise to the brain (NICE 1.1.2) “a history of malignancy known to metastasise to the brain” | [2012] | NICE 2025 |
| Be alert to medication overuse headache (NICE) “paracetamol, aspirin or an NSAID, either alone or in any combination, on 15 days per month or more. [2012]” | [2012] | NICE 2025 |
| Ask about headache at telephone triage and consider ICANS or CRS “Do you have a headache? consider ICANS/CRS” | not graded (toolkit guidance) | UK Oncology Nursing Society (UKONS) 2024 |
| After acalabrutinib is started, recommend paracetamol or caffeine and avoid NSAIDs if possible “After treatment initiation: recommend the use of acetaminophen or caffeine and avoid NSAIDs if possible” | not graded (narrative review, written with AstraZeneca-funded support) | Frontiers in Oncology (O'Brien, Brown, Byrd, Furman et al.; medical writing funded by AstraZeneca, several authors declare AstraZeneca or Acerta ties) 2021 |
| Acalabrutinib headache resolves with extended treatment; paracetamol with or without caffeine is often effective “Headache has been reported to resolve with extended treatment, and the administration of acetaminophen with or without caffeine is often effective for symptomatic relief.” | not graded (narrative review) | Hematology, American Society of Hematology Education Program (Lipsky and Lamanna; one author declares advisory roles and research support from manufacturers including AstraZeneca) 2020 |
| Acalabrutinib headache can be managed mostly without intervention, or with paracetamol or caffeine, avoiding NSAIDs if possible | not graded (narrative section of a consensus; no recommendation category attached) | Experimental Hematology & Oncology (Song et al.; states no funding and no competing interests) 2023 |
| Headache on blinatumomab may represent ICANS (table footnote) “May represent ICANS.” | not graded (regulatory label) | Amgen / US FDA (DailyMed) 2026 |
| Neurological examination before blinatumomab and clinical monitoring during it | not graded (regulatory label) | Amgen / European Medicines Agency 2026 |
| Acalabrutinib: interrupt for grade 3 or greater non-haematological toxicity; discontinue at the fourth occurrence “Discontinue Calquence.” | not graded (regulatory label) | AstraZeneca / European Medicines Agency 2026 |
| Talazoparib: after withholding for a grade 3 or 4 non-haematological reaction, consider resuming at the next lower dose or discontinue (EU wording) | not graded (regulatory label) | Pfizer / European Medicines Agency 2025 |
Shares T-cell engaging bispecific antibodies: step-up dosing, monitoring and outpatient delivery, Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids, Cytokine release syndrome (CRS).
Shares ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management, Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids, ICANS (neurotoxicity), Cytokine release syndrome (CRS).
Shares ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management, Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids, ICANS (neurotoxicity), Cytokine release syndrome (CRS).
Shares ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management, ICANS (neurotoxicity).
Shares ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management, Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids, Cytokine release syndrome (CRS).
Shares T-cell engaging bispecific antibodies: step-up dosing, monitoring and outpatient delivery, Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids, Cytokine release syndrome (CRS).
Shares ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management, Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids, ICANS (neurotoxicity), Cytokine release syndrome (CRS).
Shares Atrial fibrillation, bleeding and high blood pressure on BTK inhibitors: assessment, monitoring and management, Acalabrutinib.